Biotricity (OTCMKTS:BTCY) Releases Earnings Results, Beats Estimates By $0.04 EPS

Biotricity (OTCMKTS:BTCY) issued its quarterly earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04, Zacks reports.

Here are the key takeaways from Biotricity’s conference call:

• Biotricity reported 10.2% year-over-year revenue growth to $4.0M and improved gross margin to 81.5%, with technology fees comprising 91.2% of revenue.
• The company achieved its third consecutive quarter of positive EBITDA ($280k) and six straight quarters of positive free cash flow, and management expects to reach net-income positive in 2026.
• Despite progress, Biotricity still recorded a net loss of $1.1M for the quarter (loss per share $0.042), so profitability has not yet been achieved on the GAAP bottom line.
• Management highlighted product and regulatory momentum, including expansion of the Cardiac AI Cloud, pursuit of FDA clearance for its AI clinical model, ongoing international approvals, and growth of the consumer Bioheart and digital ecosystem to over 44,000 users.
• Commercial traction is building with deeper penetration of the Biotres Pro device, multiple large-scale hospital pilot programs, and contracts with three major GPOs giving access to over 90% of U.S. hospitals.

Biotricity Price Performance

OTCMKTS BTCY traded down $0.05 on Wednesday, hitting $0.24. 240,951 shares of the stock were exchanged, compared to its average volume of 61,520. The company’s 50-day moving average price is $0.32 and its two-hundred day moving average price is $0.47. Biotricity has a 52-week low of $0.20 and a 52-week high of $0.83. The company has a market capitalization of $6.71 million, a price-to-earnings ratio of -1.41 and a beta of 1.52.

Biotricity Company Profile

Biotricity (OTCMKTS:BTCY) is a medical device and digital health company specializing in remote cardiovascular monitoring and chronic disease management. The company’s flagship offering, the Bioflux system, integrates a wearable ECG patch with a cloud-based analytics platform to deliver real-time heart rhythm data and diagnostic insights. By combining wireless biosensors, mobile applications, and secure data transmission, Biotricity aims to simplify patient monitoring for healthcare providers and enhance early detection of arrhythmias and other cardiac events.

In addition to its core ambulatory ECG solution, Biotricity provides a suite of digital health products designed for broader chronic care management.